Catalog No.
Product Name
Application
Product Information
Citations
-
Akt Inhibitor
Uprosertib hydrochloride is a potent and selective pan-Akt inhibitor, characterized by IC50 values of 180 nM for Akt1, 328 nM for Akt2, and 38 nM for Akt3. This compound effectively modulates Akt signaling pathways, which are crucial in regulating cell growth, proliferation, and survival. Uprosertib hydrochloride is widely utilized in cancer research and therapeutic studies to explore potential treatments targeting the Akt pathway. -
Akt inhibitor
PX-316 is a selective Akt inhibitor that demonstrates the ability to phosphorylate Akt while leaving PDK1 and PKC phosphorylation unaffected. Notably, PX-316 also enhances the expression of various mitochondrial-related genes. This compound serves as a valuable tool for investigating pathways involved in colon and breast cancer research. -
PI3K/Akt/Ras/Raf/MAPK Inhibitor
Erufosine is a potent inhibitor of the PI3K/Akt and Ras/Raf/MAPK signaling pathways. It demonstrates significant cytotoxic activity against breast cancer cell lines, specifically MCF-7 and MDA-MB-231, with IC50 values of 40.95 μM and 40.8 μM, respectively. By reducing the phosphorylation levels of PI3K (p85), Akt (PKB), and cRaf, Erufosine serves as a valuable tool in the research of breast cancer and myeloid leukemia. -
PI3K/AKT/mTOR Inhibitor
PI3K/Akt/mTOR-IN-3 is a potent inhibitor targeting the PI3K/AKT/mTOR signaling pathway. It demonstrates significant biological activity, exhibiting IC50 values of 0.77 μM, 1.23 μM, and 4.57 μM in MCF-7, HeLa, and HepG2 cells, respectively. Additionally, this compound effectively inhibits the migration of MCF-7 and HeLa cells at a concentration of 4 μM, while also inducing apoptosis and causing cell cycle arrest in the S phase. This makes PI3K/Akt/mTOR-IN-3 a valuable tool for research in cancer biology and therapeutic development. -
AKT1 Inhibitor
Akt1-IN-8 is a selective inhibitor of AKT1 kinase, demonstrating high potency with an IC50 of 8.8 nM. This compound exhibits significant antiproliferative activity against PC-3 prostate cancer cells, with an IC50 of 3.0 μM. Akt1-IN-8 effectively reduces levels of phosphorylated GSK3β, making it a valuable tool for studying AKT signaling pathways in cancer research and therapeutic development. -
Akt Inhibitor
WF-10129 is a cytotoxic steroidal compound isolated from the plant Physalis. WF-10129 inhibits liver cancer cell proliferation, induces apoptosis, interferes with metabolism, and significantly reduces lactate production in vitro and in vivo. WF-10129 can also exert anti-tumor activity by regulating the expression of related genes and proteins through the AKT-p53 pathway. -
PI3K/AKT Inhibitor
PI3K/AKT-IN-3 is a selective inhibitor of the PI3K/AKT signaling pathway, known to induce both autophagy and apoptosis in various cell types. This compound is primarily utilized in cancer research to study the effects of PI3K/AKT inhibition on tumor growth and cell survival mechanisms. Its application extends to exploring therapeutic strategies targeting this critical signaling pathway in cancer treatment. -
PI3K/AKT/BMP-2/p38/ERK 1/2 Modulator
Asperosaponin V is an indirect modulator of key signaling pathways, including PI3K/AKT, BMP-2/p38, and ERK 1/2. This compound stimulates the proliferation of marrow stromal cells and promotes differentiation into osteoblasts, making it valuable for studying bone metabolism. Asperosaponin V holds potential for applications in osteoporosis research and fracture healing studies. -
Akt1 Inhibitor
Akt1-IN-6 is a potent Akt1 inhibitor with an IC50 of less than 15 nM. This compound selectively targets the Akt1 kinase, disrupting downstream signaling pathways involved in cell survival and metabolism. It is primarily used in research applications focused on cancer biology, metabolism, and other Akt-related pathways. Its high specificity for Akt1 makes it a valuable tool for studying the roles of this kinase in various disease processes. -
PI3K/AKT/mTOR Modulator
Anticancer agent 235 is a modulator of the PI3K/AKT/mTOR signaling pathway. It promotes reactive oxygen species (ROS) generation and decreases mitochondrial membrane potential, leading to reduced proliferation of cancer cell lines including HCT116, Caco-2, AGS, and SMMC-772 with IC50 values ranging from 0.35 to 26.9 μM. Furthermore, Anticancer agent 235 effectively induces G2/M cell cycle arrest and apoptosis in HCT116 cells, making it a valuable tool for cancer research applications. -
Akt Inhibitor
5,4'-Dihydroxy-6,8-dimethoxy-7-O-rhamnosyl flavone is a potent Akt inhibitor derived from Indigofera ovata. This compound effectively disrupts the PI3K/AKT and NF-κB signaling pathways, leading to the inhibition of cancer cell invasion and migration. Its biological activity supports research applications in cancer therapeutics and molecular signaling studies. -
Akt3 Inhibitor
Akt3 ligand-1 is a potent inhibitor of Akt3, exhibiting an IC50 of 0.1 nM. This compound serves as a ligand for the development of PROTAC strategies targeting Akt3, facilitating targeted protein degradation. Akt3 ligand-1 is invaluable for research into cancer biology and cellular signaling pathways where Akt3 plays a pivotal role. Additionally, it can be utilized to synthesize PROTAC Akt3 Degrader-1, enabling further exploration of therapeutic potentials in oncological studies. -
Akt1 Inhibitor
Akt1-IN-7 is a potent Akt1 inhibitor with an IC50 value of less than 15 nM. It effectively hinders the activity of Akt1, a key player in cell survival and growth signaling pathways. This compound is utilized in research focused on cancer biology, metabolic disorders, and other conditions where Akt1 signaling is implicated. Its selective inhibition of Akt1 makes it a valuable tool for elucidating the role of this kinase in various biological processes. -
PI3K/AKT Activator
Monomethyl lithospermate serves as a PI3K/AKT pathway activator, which is crucial for neuroprotection following nerve injury. This compound enhances the viability of SH-SY5Y neuroblastoma cells by preserving mitochondrial membrane potential and inhibiting apoptosis. Additionally, monomethyl lithospermate reduces oxidative stress in brain tissue of rats subjected to middle cerebral artery occlusion, demonstrating efficacy in mitigating nerve damage associated with ischemic stroke. -
Akt Inhibitor
Monosialoganglioside GM3 (bovine) is a ganglioside that functions as an Akt inhibitor, impacting both VEGFR2 and Akt signaling pathways. At a concentration of 20 μM, it effectively inhibits angiogenesis and decreases the proliferation and migration of human umbilical vein endothelial cells (HUVECs). Additionally, it protects against ferroptosis, which is relevant in the context of abdominal aortic aneurysm formation, and impairs insulin signaling by disrupting the insulin receptor-Caveolin-1 complex, contributing to insulin resistance in adipocytes. This reagent is applicable in cancer and metabolic disease research. -
AKT1-E17K Inhibitor
Akt1-IN-4 is a selective inhibitor of the AKT1-E17K mutant with an IC50 value of less than 15 nM. This compound effectively disrupts the activity of the AKT signaling pathway, which is implicated in various cancers. Akt1-IN-4 is suitable for research applications focused on studying the role of AKT1 mutations in tumorigenesis and therapeutic resistance. -
Akt Inhibitor
Puquitinib is a selective Akt inhibitor that effectively disrupts the PI3K/AKT/mTOR signaling pathway, promoting autophagy in nasopharyngeal carcinoma cells. This compound demonstrates a dose-dependent antiproliferative effect on CNE-2 cells, which is accompanied by increased autophagosome and autolysosome formation as confirmed by fluorescence and electron microscopy. Puquitinib enhances the conversion of LC3-I to LC3-II and elevates beclin 1 levels while decreasing p62 expression. Additionally, it induces apoptosis in CNE-2 cells, highlighting the interplay between autophagy and apoptosis in mediating cell death processes relevant to cancer research. -
Akt Inhibitor
TAT-TCL1-Akt-in is an Akt inhibitor that selectively modulates the Akt signaling pathway, which is crucial for cell proliferation and survival. By inhibiting Akt activity, this compound can effectively impact various cellular processes linked to tumorigenesis and cancer progression. TAT-TCL1-Akt-in is useful for research applications focused on cancer biology, signaling pathways, and therapeutic interventions targeting the Akt pathway. -
AKT Inhibitor
BI-69A11 is a selective AKT inhibitor that effectively suppresses the phosphorylation of AKT, disrupting the signaling pathways associated with cell survival and proliferation. This compound demonstrates significant anticancer activity, promoting apoptosis in melanoma and prostate tumor cells. It serves as a valuable tool for research in cancer biology and therapeutic development targeting the AKT pathway. -
mTOR/PI3/AKT Inhibitor
Royleanone, a diterpenoid isolated from plants, inhibits the proliferation of cancer cells by inducing cell cycle arrest and mitochondria-mediated apoptosis, also inhibits cell migration potential, inhibits mTOR/PI3/AKT signaling pathway in LNCaP prostate cancer cells. -
AKT Degrader
MS5033 is a potent PROTAC-based degrader targeting AKT (protein kinase B). It demonstrates a DC50 value of 430 nM in PC3 cells, effectively promoting the degradation of AKT. This compound is valuable for studying AKT signaling pathways and evaluating the therapeutic potential of targeted protein degradation in cancer research. -
PI3K/Akt/FoxO3a Inhibitor
RLX hydrochloride is a potent inhibitor of the PI3K/Akt/FoxO3a signaling pathway, which plays a critical role in cellular growth and survival. This compound demonstrates significant therapeutic potential in experimental colon cancer by modulating the tumor microenvironment and enhancing the efficacy of cancer immunotherapy. Additionally, RLX hydrochloride can improve the retention of therapeutic agents within tumors when utilized with advanced nanoparticle delivery systems. It may also be effectively combined with other treatment modalities, such as chemotherapy and radiotherapy, to optimize overall cancer therapy outcomes. -
AKT Inhibitor
AKT-IN-9 is a potent inhibitor of AKT (Protein Kinase B), a key regulator of the PI3K/AKT/mTOR signaling pathway. This compound plays a critical role in processes such as cell growth, survival, differentiation, and metabolism. AKT-IN-9 is valuable for research applications focusing on breast and prostate cancer, contributing to a better understanding of tumor biology and potential therapeutic strategies. -
Tubulin/AKT1 Inhibitor
Tubulin/AKT1-IN-1 is an inhibitor of tubulin polymerization and AKT pathway activation. This compound demonstrates significant inhibition of proliferation and metastasis in H1975 cells, along with a modest induction of apoptosis. Tubulin/AKT1-IN-1 is particularly relevant for research in non-small cell lung cancer (NSCLC), providing a valuable tool for studying therapeutic strategies against this malignancy. -
Akt Inhibitor
AKT-IN-12 is a selective Akt kinase inhibitor, exhibiting an IC50 value of 0.55 μM. It effectively induces G0/G1 cell cycle arrest and promotes apoptosis in target cells. Additionally, AKT-IN-12 inhibits phosphorylated AKT and ERK while activating JNK and phosphorylated JNK, making it a valuable reagent for research applications in leukemia studies. -
AKT Inhibitor
AKT-IN-20 is a selective inhibitor of the AKT kinase, a key regulator in numerous signaling pathways involved in cell growth, survival, and metabolism. This compound effectively impedes AKT activity, making it valuable for the study of cancer mechanisms and the exploration of potential therapeutic strategies. Its application is essential for researchers investigating the role of AKT in tumorigenesis and treatment resistance. -
Akt1 synthesis reducer
Archexin is an antisense oligonucleotide designed to inhibit the synthesis of Akt1. This reagent effectively reduces Akt1 expression, making it a valuable tool for studying the role of Akt signaling in metastatic renal cancer. Its application in research facilitates the exploration of potential therapeutic strategies targeting the Akt pathway. -
Akt Inhibitor
Ipatasertib tosylate is a potent and selective ATP-competitive inhibitor of pan-Akt, exhibiting IC50 values of 5, 18, and 8 nM for Akt1, Akt2, and Akt3, respectively. By inhibiting Akt, Ipatasertib tosylate activates FoxO3a and NF-κB, resulting in p53-independent activation of PUMA and subsequent apoptosis in cancer cells. This compound demonstrates significant anti-tumor activity in xenograft mouse models, making it a valuable tool for cancer research and therapeutic development. -
AKT Inhibitor
AKT-IN-22 is a potent allosteric inhibitor of AKT, a key kinase involved in various cellular processes such as proliferation, survival, and glucose metabolism. Its inhibition of AKT has demonstrated significant anticancer effects, making it a valuable tool for cancer research. This compound is particularly useful for studying the mechanisms of AKT signaling pathways and exploring therapeutic strategies in oncology. -
Akt Inhibitor
Doxazosin hydrochloride is an Akt inhibitor that primarily targets postsynaptic α1-adrenoceptors in vascular smooth muscle. This compound exhibits vasodilatory effects, resulting in decreased peripheral vascular resistance, and is utilized in studies of hypertension and prostate hyperplasia. Additionally, Doxazosin hydrochloride has demonstrated the ability to inhibit the proliferation and migration of hepatic stellate cells in mouse liver fibrosis models, influencing fibrosis, autophagy, and apoptosis mechanisms through the activation of the PI3K/Akt/mTOR signaling pathway. It also disrupts autophagic flux, leading to enhanced apoptosis in hepatic stellate cells. -
Akt Inhibitor
AKT-IN-25 is a selective inhibitor of Akt that targets its phosphorylation, thereby disrupting the PI3K/Akt/mTOR signaling pathway. This compound effectively arrests the cell cycle at the G1 phase and inhibits the migration and proliferation of pancreatic cancer cells, including PANC-1, PATU-T, and SUIT-2, with IC50 values of 3.05 μM, 1.32 μM, and 3.85 μM, respectively. AKT-IN-25 is a valuable tool for studying Akt-mediated cellular processes and therapeutic strategies in cancer research. -
PI3K/Akt Inhibitor
Acetyl-Exenatide is an acetylated derivative of Exenatide, targeting the PI3K/Akt signaling pathway. This compound exhibits insulin-mimetic properties and is instrumental in type 2 diabetes research. Acetyl-Exenatide promotes Th17 differentiation while inhibiting Treg differentiation, and downregulates the phosphorylation of PI3K/Akt/FoxO1, making it a valuable tool for elucidating mechanisms underlying metabolic disorders. -
AKT Inhibitor
SH-5 is a potent inhibitor of the AKT signaling pathway. It enhances apoptosis triggered by tumor necrosis factor (TNF) and effectively blocks NF-kB activation induced by TNF-α, lipopolysaccharide, phorbol ester, and cigarette smoke. This compound is valuable for research applications involving cell survival, inflammation, and cancer biology. -
Topo-IIα/Akt Inhibitor
NISC-6 is a dual inhibitor of Topoisomerase IIα and Akt, demonstrating significant inhibitory activity in various cancer cell lines, including UACC903 (IC50 = 2.5 µM) and CHL-1 (IC50 = 0.8 µM). This compound effectively induces both early and late apoptosis in a dose-dependent manner. NISC-6 is suitable for research focusing on melanoma and related therapeutic mechanisms. -
Akt/SKG Substrate
Akt/SKG Substrate Peptide is a synthetic peptide specifically designed as a substrate for Akt/PKB. This peptide is selectively phosphorylated by Akt/PKB and does not undergo phosphorylation by p70S6K or MAPK1, making it an ideal tool for studying the Akt signaling pathway. Its specificity is valuable in research applications focused on cancer, metabolism, and neurological disorders associated with Akt dysregulation. -
PI3K/Akt/mTOR Inhibitor、MAPK Inhibitor、NF-κB Inhibitor
Calebin A is a potent inhibitor of the PI3K/Akt/mTOR pathway, as well as MAPK and NF-κB signaling pathways. It exhibits significant anti-tumor activity through epigenetic regulation and can suppress apoptosis while inhibiting autophagy. Additionally, Calebin A modulates adipogenesis, enhances thermogenic processes, and supports gut microbiota. This compound is suitable for research in various domains, including osteoarthritis, Alzheimer's disease, type 2 diabetes, malignant peripheral nerve sheath tumors, and colorectal cancer. -
AKT1 Inhibitor
AKT1-IN-11 is a dual inhibitor targeting both AKT1 and tubulin, derived from Podophyllotoxin. This compound effectively down-regulates the phosphorylation of AKT kinase in tumor cells, leading to inhibited cell proliferation, a G2/M phase arrest, and the induction of apoptosis. Additionally, AKT1-IN-11 promotes tubulin depolymerization, making it a valuable tool for research into colorectal cancer and potential therapeutic strategies. -
Akt
N-Arachidonoyl-L-serine is an endocannabinoid that primarily targets Akt to induce phosphorylation in endothelial cells. It facilitates endothelium-dependent vasodilation in isolated rat mesenteric and abdominal aortas. Additionally, N-Arachidonoyl-L-serine demonstrates neuroprotective effects following traumatic brain injury by reducing apoptosis. It also promotes the opening of KV7.1/KCNE1 channels in mammalian cells, shortening action potential duration in cardiomyocytes. This compound is valuable for research in cardiovascular, cerebrovascular, and neurological disorders. -
Akt1 Inhibitor
Akt1-IN-5 is a potent Akt1 inhibitor with an IC50 of less than 15 nM. This compound selectively targets the Akt1 signaling pathway, which is crucial in regulating cell survival, metabolism, and proliferation. It is primarily used in cancer research to explore the therapeutic potential of modulating Akt1 activity in various tumor types. -
Akt Inducer
AS1938909 is a selective Akt inducer that inhibits SHIP2 activity, leading to increased phosphorylation of Akt. This compound plays a crucial role in the regulation of glucose metabolism by upregulating GLUT1 gene expression. AS1938909 is valuable for research applications focused on metabolic disorders and signaling pathways involving Akt and SHIP2. -
AKT1/PKA Inhibitor
Akt1&PKA-IN-2 (Compound R-29) is a AKT1 and PKA inhibitor with selectivity for CDK2, with IC50 values of 0.007 and 0.01 μM, respectively. Akt1&PKA-IN-2 is applicable for cancer research. -
Akt/p70S6K Inhibitor
XL-418 is a potent dual inhibitor of Akt and p70S6K, demonstrating IC50 values of 1 nM for Akt1 and 2 nM for p70S6K. This compound effectively inhibits the phosphorylation of ribosomal protein S6 and GSK3β, making it a valuable tool in cancer research. XL-418 is particularly relevant for studies involving prostate carcinoma and breast cancer, contributing to the understanding of signaling pathways in tumorigenesis. -
PROTAC AKT Degrader
MS143 is a potent PROTAC degrader targeting AKT, demonstrating a DC50 of 46 nM and GI50 of 0.8 μM in PC3 cells. This compound effectively induces rapid and robust AKT degradation through the hijacking of the ubiquitin-proteasome system in a concentration- and time-dependent manner. MS143 holds promise in cancer research for its ability to suppress cell growth by promoting targeted protein degradation. -
AKT Inhibitor
AKT-IN-23 is a selective inhibitor of the AKT kinase, a crucial component in the PI3K/AKT signaling pathway. This compound effectively inhibits AKT activity, leading to decreased cell proliferation and survival in various cancer cell models. AKT-IN-23 is useful in cancer research, particularly in studies focused on the modulation of signaling pathways associated with tumor progression and therapeutic resistance. -
Akt Inhibitor
Hu7691 free base is a selective inhibitor of AKT, demonstrating IC50 values of 4.0 nM, 97.5 nM, and 28 nM for AKT1, AKT2, and AKT3, respectively. This compound exhibits significant antitumor activity and has been shown to reduce cutaneous toxicity in murine models. Hu7691 free base is valuable in research focused on cancer therapeutics and the modulation of the AKT signaling pathway. -
PROTAC AKT Degrader
MS98 is a selective PROTAC degrader targeting AKT, effectively inducing the degradation of total AKT (T-AKT) with a DC50 value of 78 nM. This compound demonstrates high-affinity binding to AKT isoforms, with Kd values of 4 nM, 140 nM, and 8.1 nM for AKT1, AKT2, and AKT3, respectively. MS98 is valuable for research applications in understanding AKT signaling pathways and developing therapeutic strategies for cancer and other diseases associated with dysregulated AKT activity. -
AKT Inhibitor
AT7867 hydrochloride is a potent inhibitor of AKT and p70 S6 kinase, exhibiting strong oral activity. This compound demonstrates significant anticancer properties, making it a valuable tool in cancer research. Its efficacy in targeting critical signaling pathways involved in cellular growth and survival supports its use in exploring therapeutic strategies for various malignancies. -
Allosteric Akt Inhibitor
MK-2206 free base is a highly potent and selective allosteric inhibitor of the Akt signaling pathway, exhibiting IC50 values of 8 nM, 12 nM, and 65 nM for Akt1, Akt2, and Akt3, respectively. This compound demonstrates significant anticancer properties, particularly against breast cancer cell lines, as well as those harboring PIK3CA mutations and PTEN loss. MK-2206 free base is valuable for research applications focused on cancer biology and therapeutic development targeting the Akt pathway. -
Akt1/Akt2 Inhibitor
AKT-IN-5 is a selective inhibitor of Akt1 and Akt2, exhibiting IC50 values of 450 nM and 400 nM, respectively. This compound has been shown to effectively modulate the Akt signaling pathway, which plays a critical role in cell survival, proliferation, and metabolism. AKT-IN-5 is valuable for research applications focused on cancer biology, metabolic disorders, and other conditions driven by aberrant Akt activity.
